Free Trial

Smith & Nephew SNATS, Inc. (NYSE:SNN) Sees Significant Increase in Short Interest

Smith & Nephew logo with Medical background

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) saw a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 2,910,000 shares, a growth of 54.8% from the May 15th total of 1,880,000 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average trading volume of 839,100 shares, the short-interest ratio is currently 3.5 days.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. HSBC lowered Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group lifted their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res lowered Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Wall Street Zen upgraded Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Finally, UBS Group lowered Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Six analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $28.00.

Check Out Our Latest Stock Report on SNN

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN traded down $0.11 during trading on Thursday, reaching $28.53. 890,947 shares of the company traded hands, compared to its average volume of 804,309. Smith & Nephew SNATS has a 12-month low of $23.69 and a 12-month high of $31.72. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62. The stock has a market cap of $12.49 billion, a P/E ratio of 13.21, a PEG ratio of 0.88 and a beta of 0.68. The firm's fifty day simple moving average is $28.22 and its 200 day simple moving average is $26.92.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors have recently modified their holdings of the business. Hexagon Capital Partners LLC grew its position in shares of Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 406 shares during the period. Richards Merrill & Peterson Inc. grew its position in shares of Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 1,000 shares during the period. Principal Securities Inc. grew its position in shares of Smith & Nephew SNATS by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 691 shares during the period. National Bank of Canada FI grew its position in shares of Smith & Nephew SNATS by 36.5% during the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after acquiring an additional 446 shares during the period. Finally, Bessemer Group Inc. grew its position in shares of Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,701 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Read More

Should You Invest $1,000 in Smith & Nephew SNATS Right Now?

Before you consider Smith & Nephew SNATS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.

While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines